Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 7Gynecologic 6Genitourinary 6Gastrointestinal 6Other hematologic neoplasm 3Head & Neck 3Tumor-Agnostic 2CNS 2Breast 2Plasma cell 1Other 1Dermatologic 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 296Cytarabine 261fludarabine phosphate 218Rituximab 195fludarabine 182Methotrexate 152Whole-Body Irradiation 140Mycophenolic Acid 124Azacitidine 122Tacrolimus 116Busulfan 110Filgrastim 104Granulocyte Colony-Stimulating Factor 98Etoposide 91Peripheral Blood Stem Cell Transplantation 90Dexamethasone 89Vincristine 88Melphalan 80Cyclosporine 74Lenalidomide 73Daunorubicin 70Decitabine 69Clofarabine 69Antilymphocyte Serum 67Calcium Dobesilate 61venetoclax 60Doxorubicin 58Imatinib Mesylate 57Alemtuzumab 56ibrutinib 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Saline Solution × Other hematologic neoplasm × Clear all
NCT04571645 2024-04-15

AML

Jazz Pharmaceuticals

Phase 3 Terminated
9 enrolled 9 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02663622 2024-01-23

MK-7110-002

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
44 enrolled 27 charts
Other hematologic neoplasm

Graft vs Host Disease, Leukemia

NCT01687387 2019-02-08

EFFIKIR

Innate Pharma

Phase 2 Completed
152 enrolled 9 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡